nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—ABCB1—Topotecan—cervical cancer	0.0696	0.625	CbGbCtD
Carvedilol—CYP3A4—Topotecan—cervical cancer	0.0417	0.375	CbGbCtD
Carvedilol—NDUFC2—exocrine gland—cervical cancer	0.0108	0.0288	CbGeAlD
Carvedilol—Paresis—Topotecan—cervical cancer	0.0108	0.0807	CcSEcCtD
Carvedilol—SELE—epithelium—cervical cancer	0.00631	0.0168	CbGeAlD
Carvedilol—SELE—uterine cervix—cervical cancer	0.00625	0.0166	CbGeAlD
Carvedilol—SELE—renal system—cervical cancer	0.00585	0.0155	CbGeAlD
Carvedilol—VCAM1—epithelium—cervical cancer	0.0058	0.0154	CbGeAlD
Carvedilol—VCAM1—uterine cervix—cervical cancer	0.00575	0.0153	CbGeAlD
Carvedilol—Neuralgia—Topotecan—cervical cancer	0.00567	0.0424	CcSEcCtD
Carvedilol—HIF1A—epithelium—cervical cancer	0.00558	0.0148	CbGeAlD
Carvedilol—Interstitial lung disease—Topotecan—cervical cancer	0.00557	0.0416	CcSEcCtD
Carvedilol—Lung disorder—Topotecan—cervical cancer	0.00557	0.0416	CcSEcCtD
Carvedilol—HIF1A—uterine cervix—cervical cancer	0.00554	0.0147	CbGeAlD
Carvedilol—VCAM1—decidua—cervical cancer	0.00548	0.0146	CbGeAlD
Carvedilol—SELE—mammalian vulva—cervical cancer	0.00547	0.0145	CbGeAlD
Carvedilol—GJA1—epithelium—cervical cancer	0.00542	0.0144	CbGeAlD
Carvedilol—VCAM1—renal system—cervical cancer	0.00538	0.0143	CbGeAlD
Carvedilol—GJA1—uterine cervix—cervical cancer	0.00537	0.0143	CbGeAlD
Carvedilol—HIF1A—decidua—cervical cancer	0.00527	0.014	CbGeAlD
Carvedilol—SELE—uterus—cervical cancer	0.00521	0.0138	CbGeAlD
Carvedilol—VCAM1—endometrium—cervical cancer	0.0052	0.0138	CbGeAlD
Carvedilol—HIF1A—renal system—cervical cancer	0.00518	0.0138	CbGeAlD
Carvedilol—Rash erythematous—Topotecan—cervical cancer	0.00514	0.0384	CcSEcCtD
Carvedilol—GJA1—decidua—cervical cancer	0.00512	0.0136	CbGeAlD
Carvedilol—VCAM1—mammalian vulva—cervical cancer	0.00503	0.0134	CbGeAlD
Carvedilol—GJA1—renal system—cervical cancer	0.00502	0.0133	CbGeAlD
Carvedilol—HIF1A—endometrium—cervical cancer	0.00501	0.0133	CbGeAlD
Carvedilol—GJA1—endometrium—cervical cancer	0.00486	0.0129	CbGeAlD
Carvedilol—HIF1A—mammalian vulva—cervical cancer	0.00484	0.0129	CbGeAlD
Carvedilol—VCAM1—uterus—cervical cancer	0.00479	0.0127	CbGeAlD
Carvedilol—NDUFC2—epithelium—cervical cancer	0.00471	0.0125	CbGeAlD
Carvedilol—GJA1—mammalian vulva—cervical cancer	0.0047	0.0125	CbGeAlD
Carvedilol—SELE—female reproductive system—cervical cancer	0.00469	0.0124	CbGeAlD
Carvedilol—NDUFC2—uterine cervix—cervical cancer	0.00467	0.0124	CbGeAlD
Carvedilol—HIF1A—uterus—cervical cancer	0.00461	0.0123	CbGeAlD
Carvedilol—GJA1—uterus—cervical cancer	0.00448	0.0119	CbGeAlD
Carvedilol—NDUFC2—decidua—cervical cancer	0.00445	0.0118	CbGeAlD
Carvedilol—NDUFC2—renal system—cervical cancer	0.00437	0.0116	CbGeAlD
Carvedilol—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00433	0.0324	CcSEcCtD
Carvedilol—VCAM1—female reproductive system—cervical cancer	0.00431	0.0114	CbGeAlD
Carvedilol—SELE—female gonad—cervical cancer	0.00426	0.0113	CbGeAlD
Carvedilol—VEGFA—uterine cervix—cervical cancer	0.00424	0.0113	CbGeAlD
Carvedilol—SELE—vagina—cervical cancer	0.00424	0.0113	CbGeAlD
Carvedilol—NDUFC2—endometrium—cervical cancer	0.00423	0.0112	CbGeAlD
Carvedilol—HIF1A—female reproductive system—cervical cancer	0.00415	0.011	CbGeAlD
Carvedilol—NDUFC2—mammalian vulva—cervical cancer	0.00409	0.0109	CbGeAlD
Carvedilol—VEGFA—decidua—cervical cancer	0.00404	0.0107	CbGeAlD
Carvedilol—GJA1—female reproductive system—cervical cancer	0.00402	0.0107	CbGeAlD
Carvedilol—VCAM1—female gonad—cervical cancer	0.00392	0.0104	CbGeAlD
Carvedilol—VCAM1—vagina—cervical cancer	0.0039	0.0104	CbGeAlD
Carvedilol—NDUFC2—uterus—cervical cancer	0.0039	0.0103	CbGeAlD
Carvedilol—VEGFA—endometrium—cervical cancer	0.00383	0.0102	CbGeAlD
Carvedilol—XDH—uterine cervix—cervical cancer	0.00377	0.01	CbGeAlD
Carvedilol—HIF1A—female gonad—cervical cancer	0.00377	0.01	CbGeAlD
Carvedilol—HIF1A—vagina—cervical cancer	0.00375	0.00996	CbGeAlD
Carvedilol—VEGFA—mammalian vulva—cervical cancer	0.00371	0.00985	CbGeAlD
Carvedilol—ADRB3—female reproductive system—cervical cancer	0.00369	0.00979	CbGeAlD
Carvedilol—GJA1—female gonad—cervical cancer	0.00366	0.00972	CbGeAlD
Carvedilol—GJA1—vagina—cervical cancer	0.00364	0.00966	CbGeAlD
Carvedilol—Rash maculo-papular—Topotecan—cervical cancer	0.00358	0.0268	CcSEcCtD
Carvedilol—VEGFA—uterus—cervical cancer	0.00353	0.00939	CbGeAlD
Carvedilol—XDH—renal system—cervical cancer	0.00353	0.00938	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—cervical cancer	0.0035	0.0093	CbGeAlD
Carvedilol—XDH—endometrium—cervical cancer	0.00341	0.00907	CbGeAlD
Carvedilol—ADRB3—female gonad—cervical cancer	0.00335	0.00891	CbGeAlD
Carvedilol—XDH—mammalian vulva—cervical cancer	0.0033	0.00877	CbGeAlD
Carvedilol—NDUFC2—female gonad—cervical cancer	0.00319	0.00846	CbGeAlD
Carvedilol—NDUFC2—vagina—cervical cancer	0.00317	0.00841	CbGeAlD
Carvedilol—Anaphylactoid reaction—Topotecan—cervical cancer	0.00295	0.0221	CcSEcCtD
Carvedilol—VEGFA—female gonad—cervical cancer	0.00289	0.00768	CbGeAlD
Carvedilol—VEGFA—vagina—cervical cancer	0.00287	0.00763	CbGeAlD
Carvedilol—XDH—female reproductive system—cervical cancer	0.00283	0.00751	CbGeAlD
Carvedilol—ADRA1D—epithelium—cervical cancer	0.00279	0.00742	CbGeAlD
Carvedilol—SELE—lymph node—cervical cancer	0.00274	0.00728	CbGeAlD
Carvedilol—Cardiac arrest—Topotecan—cervical cancer	0.00272	0.0203	CcSEcCtD
Carvedilol—ADRA1B—renal system—cervical cancer	0.00265	0.00704	CbGeAlD
Carvedilol—Cramp muscle—Topotecan—cervical cancer	0.00258	0.0192	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00258	0.0192	CcSEcCtD
Carvedilol—XDH—vagina—cervical cancer	0.00256	0.00679	CbGeAlD
Carvedilol—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00252	0.0188	CcSEcCtD
Carvedilol—VCAM1—lymph node—cervical cancer	0.00252	0.0067	CbGeAlD
Carvedilol—HIF1A—lymph node—cervical cancer	0.00243	0.00644	CbGeAlD
Carvedilol—GJA1—lymph node—cervical cancer	0.00235	0.00625	CbGeAlD
Carvedilol—Pancytopenia—Topotecan—cervical cancer	0.00235	0.0175	CcSEcCtD
Carvedilol—Weight increased—Topotecan—cervical cancer	0.00225	0.0168	CcSEcCtD
Carvedilol—Pneumonia—Topotecan—cervical cancer	0.00222	0.0166	CcSEcCtD
Carvedilol—ADRA1D—female reproductive system—cervical cancer	0.00208	0.00551	CbGeAlD
Carvedilol—NDUFC2—lymph node—cervical cancer	0.00205	0.00544	CbGeAlD
Carvedilol—Haemoglobin—Topotecan—cervical cancer	0.00199	0.0149	CcSEcCtD
Carvedilol—Rhinitis—Topotecan—cervical cancer	0.00198	0.0148	CcSEcCtD
Carvedilol—Haemorrhage—Topotecan—cervical cancer	0.00198	0.0148	CcSEcCtD
Carvedilol—Hypoaesthesia—Topotecan—cervical cancer	0.00197	0.0147	CcSEcCtD
Carvedilol—Pharyngitis—Topotecan—cervical cancer	0.00196	0.0147	CcSEcCtD
Carvedilol—VEGFA—lymph node—cervical cancer	0.00186	0.00494	CbGeAlD
Carvedilol—Angiopathy—Topotecan—cervical cancer	0.00179	0.0134	CcSEcCtD
Carvedilol—Immune system disorder—Topotecan—cervical cancer	0.00179	0.0134	CcSEcCtD
Carvedilol—Mediastinal disorder—Topotecan—cervical cancer	0.00178	0.0133	CcSEcCtD
Carvedilol—Alopecia—Topotecan—cervical cancer	0.00175	0.0131	CcSEcCtD
Carvedilol—Malnutrition—Topotecan—cervical cancer	0.00172	0.0129	CcSEcCtD
Carvedilol—Back pain—Topotecan—cervical cancer	0.00167	0.0124	CcSEcCtD
Carvedilol—Muscle spasms—Topotecan—cervical cancer	0.00166	0.0124	CcSEcCtD
Carvedilol—ADRA1A—epithelium—cervical cancer	0.0016	0.00426	CbGeAlD
Carvedilol—Ill-defined disorder—Topotecan—cervical cancer	0.0016	0.0119	CcSEcCtD
Carvedilol—Anaemia—Topotecan—cervical cancer	0.00159	0.0119	CcSEcCtD
Carvedilol—Angioedema—Topotecan—cervical cancer	0.00157	0.0118	CcSEcCtD
Carvedilol—Malaise—Topotecan—cervical cancer	0.00155	0.0116	CcSEcCtD
Carvedilol—Leukopenia—Topotecan—cervical cancer	0.00154	0.0115	CcSEcCtD
Carvedilol—KCNH2—uterine cervix—cervical cancer	0.00154	0.00408	CbGeAlD
Carvedilol—ADRA2C—uterine cervix—cervical cancer	0.00152	0.00403	CbGeAlD
Carvedilol—ADRB1—female reproductive system—cervical cancer	0.00151	0.004	CbGeAlD
Carvedilol—Cough—Topotecan—cervical cancer	0.0015	0.0112	CcSEcCtD
Carvedilol—ADRA1A—renal system—cervical cancer	0.00149	0.00395	CbGeAlD
Carvedilol—Arthralgia—Topotecan—cervical cancer	0.00147	0.011	CcSEcCtD
Carvedilol—Myalgia—Topotecan—cervical cancer	0.00147	0.011	CcSEcCtD
Carvedilol—Chest pain—Topotecan—cervical cancer	0.00147	0.011	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00146	0.0109	CcSEcCtD
Carvedilol—Discomfort—Topotecan—cervical cancer	0.00145	0.0108	CcSEcCtD
Carvedilol—ADRA2C—decidua—cervical cancer	0.00144	0.00384	CbGeAlD
Carvedilol—KCNH2—renal system—cervical cancer	0.00144	0.00382	CbGeAlD
Carvedilol—ADRA2C—renal system—cervical cancer	0.00142	0.00377	CbGeAlD
Carvedilol—Anaphylactic shock—Topotecan—cervical cancer	0.00141	0.0105	CcSEcCtD
Carvedilol—Infection—Topotecan—cervical cancer	0.0014	0.0104	CcSEcCtD
Carvedilol—KCNH2—endometrium—cervical cancer	0.00139	0.00369	CbGeAlD
Carvedilol—Thrombocytopenia—Topotecan—cervical cancer	0.00138	0.0103	CcSEcCtD
Carvedilol—ADRA2C—endometrium—cervical cancer	0.00137	0.00364	CbGeAlD
Carvedilol—Skin disorder—Topotecan—cervical cancer	0.00137	0.0102	CcSEcCtD
Carvedilol—Hyperhidrosis—Topotecan—cervical cancer	0.00136	0.0102	CcSEcCtD
Carvedilol—Anorexia—Topotecan—cervical cancer	0.00134	0.01	CcSEcCtD
Carvedilol—ADRA2C—mammalian vulva—cervical cancer	0.00133	0.00352	CbGeAlD
Carvedilol—CYP1A1—epithelium—cervical cancer	0.00131	0.00348	CbGeAlD
Carvedilol—CYP1A1—uterine cervix—cervical cancer	0.0013	0.00345	CbGeAlD
Carvedilol—KCNH2—uterus—cervical cancer	0.00128	0.0034	CbGeAlD
Carvedilol—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00128	0.00957	CcSEcCtD
Carvedilol—ADRA2C—uterus—cervical cancer	0.00126	0.00336	CbGeAlD
Carvedilol—Paraesthesia—Topotecan—cervical cancer	0.00126	0.00943	CcSEcCtD
Carvedilol—Dyspnoea—Topotecan—cervical cancer	0.00125	0.00936	CcSEcCtD
Carvedilol—Dyspepsia—Topotecan—cervical cancer	0.00124	0.00925	CcSEcCtD
Carvedilol—CYP1A2—renal system—cervical cancer	0.00123	0.00327	CbGeAlD
Carvedilol—Decreased appetite—Topotecan—cervical cancer	0.00122	0.00913	CcSEcCtD
Carvedilol—CYP1A1—renal system—cervical cancer	0.00121	0.00322	CbGeAlD
Carvedilol—Gastrointestinal disorder—Topotecan—cervical cancer	0.00121	0.00907	CcSEcCtD
Carvedilol—Fatigue—Topotecan—cervical cancer	0.00121	0.00906	CcSEcCtD
Carvedilol—ADRA2A—uterine cervix—cervical cancer	0.00121	0.00321	CbGeAlD
Carvedilol—Constipation—Topotecan—cervical cancer	0.0012	0.00898	CcSEcCtD
Carvedilol—Pain—Topotecan—cervical cancer	0.0012	0.00898	CcSEcCtD
Carvedilol—Feeling abnormal—Topotecan—cervical cancer	0.00116	0.00866	CcSEcCtD
Carvedilol—ADRA2A—decidua—cervical cancer	0.00115	0.00306	CbGeAlD
Carvedilol—KCNH2—female reproductive system—cervical cancer	0.00115	0.00306	CbGeAlD
Carvedilol—PTGS1—epithelium—cervical cancer	0.00115	0.00305	CbGeAlD
Carvedilol—Gastrointestinal pain—Topotecan—cervical cancer	0.00115	0.00859	CcSEcCtD
Carvedilol—PTGS1—uterine cervix—cervical cancer	0.00114	0.00303	CbGeAlD
Carvedilol—CYP1A1—mammalian vulva—cervical cancer	0.00114	0.00302	CbGeAlD
Carvedilol—Urticaria—Topotecan—cervical cancer	0.00112	0.00834	CcSEcCtD
Carvedilol—Abdominal pain—Topotecan—cervical cancer	0.00111	0.0083	CcSEcCtD
Carvedilol—Body temperature increased—Topotecan—cervical cancer	0.00111	0.0083	CcSEcCtD
Carvedilol—CYP2E1—renal system—cervical cancer	0.00111	0.00294	CbGeAlD
Carvedilol—ADRA2A—endometrium—cervical cancer	0.00109	0.00291	CbGeAlD
Carvedilol—CYP1A1—uterus—cervical cancer	0.00108	0.00287	CbGeAlD
Carvedilol—PTGS1—renal system—cervical cancer	0.00107	0.00283	CbGeAlD
Carvedilol—ADRA2A—mammalian vulva—cervical cancer	0.00106	0.00281	CbGeAlD
Carvedilol—KCNH2—female gonad—cervical cancer	0.00105	0.00278	CbGeAlD
Carvedilol—KCNH2—vagina—cervical cancer	0.00104	0.00277	CbGeAlD
Carvedilol—Hypersensitivity—Topotecan—cervical cancer	0.00104	0.00774	CcSEcCtD
Carvedilol—ADRA2C—female gonad—cervical cancer	0.00103	0.00275	CbGeAlD
Carvedilol—PTGS1—endometrium—cervical cancer	0.00103	0.00274	CbGeAlD
Carvedilol—ADRA2C—vagina—cervical cancer	0.00103	0.00273	CbGeAlD
Carvedilol—Asthenia—Topotecan—cervical cancer	0.00101	0.00754	CcSEcCtD
Carvedilol—ADRA2A—uterus—cervical cancer	0.00101	0.00268	CbGeAlD
Carvedilol—PTGS1—mammalian vulva—cervical cancer	0.000997	0.00265	CbGeAlD
Carvedilol—Pruritus—Topotecan—cervical cancer	0.000994	0.00743	CcSEcCtD
Carvedilol—CYP1A1—female reproductive system—cervical cancer	0.000972	0.00258	CbGeAlD
Carvedilol—Diarrhoea—Topotecan—cervical cancer	0.000962	0.00719	CcSEcCtD
Carvedilol—PTGS1—uterus—cervical cancer	0.00095	0.00252	CbGeAlD
Carvedilol—CYP2C9—female reproductive system—cervical cancer	0.000936	0.00248	CbGeAlD
Carvedilol—Dizziness—Topotecan—cervical cancer	0.000929	0.00695	CcSEcCtD
Carvedilol—ADRA2A—female reproductive system—cervical cancer	0.000906	0.00241	CbGeAlD
Carvedilol—Vomiting—Topotecan—cervical cancer	0.000894	0.00668	CcSEcCtD
Carvedilol—CYP3A4—renal system—cervical cancer	0.000891	0.00237	CbGeAlD
Carvedilol—CYP2E1—female reproductive system—cervical cancer	0.000887	0.00235	CbGeAlD
Carvedilol—Rash—Topotecan—cervical cancer	0.000886	0.00662	CcSEcCtD
Carvedilol—Dermatitis—Topotecan—cervical cancer	0.000885	0.00662	CcSEcCtD
Carvedilol—CYP1A1—female gonad—cervical cancer	0.000885	0.00235	CbGeAlD
Carvedilol—Headache—Topotecan—cervical cancer	0.00088	0.00658	CcSEcCtD
Carvedilol—CYP1A1—vagina—cervical cancer	0.000879	0.00234	CbGeAlD
Carvedilol—CYP2D6—renal system—cervical cancer	0.000877	0.00233	CbGeAlD
Carvedilol—PTGS1—female reproductive system—cervical cancer	0.000854	0.00227	CbGeAlD
Carvedilol—Nausea—Topotecan—cervical cancer	0.000835	0.00624	CcSEcCtD
Carvedilol—ADRA2A—female gonad—cervical cancer	0.000825	0.00219	CbGeAlD
Carvedilol—ADRA2A—vagina—cervical cancer	0.00082	0.00218	CbGeAlD
Carvedilol—PTGS1—female gonad—cervical cancer	0.000777	0.00206	CbGeAlD
Carvedilol—PTGS1—vagina—cervical cancer	0.000772	0.00205	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—cervical cancer	0.000713	0.00189	CbGeAlD
Carvedilol—CYP2D6—female reproductive system—cervical cancer	0.000702	0.00186	CbGeAlD
Carvedilol—ABCB1—epithelium—cervical cancer	0.00068	0.00181	CbGeAlD
Carvedilol—ABCB1—uterine cervix—cervical cancer	0.000674	0.00179	CbGeAlD
Carvedilol—KCNH2—lymph node—cervical cancer	0.000673	0.00179	CbGeAlD
Carvedilol—ADRA2C—lymph node—cervical cancer	0.000664	0.00176	CbGeAlD
Carvedilol—ABCB1—decidua—cervical cancer	0.000642	0.00171	CbGeAlD
Carvedilol—CYP2D6—female gonad—cervical cancer	0.000639	0.0017	CbGeAlD
Carvedilol—ABCB1—renal system—cervical cancer	0.000631	0.00167	CbGeAlD
Carvedilol—ABCB1—endometrium—cervical cancer	0.00061	0.00162	CbGeAlD
Carvedilol—ABCB1—mammalian vulva—cervical cancer	0.00059	0.00157	CbGeAlD
Carvedilol—CYP1A1—lymph node—cervical cancer	0.000569	0.00151	CbGeAlD
Carvedilol—ABCB1—uterus—cervical cancer	0.000562	0.00149	CbGeAlD
Carvedilol—ADRA2A—lymph node—cervical cancer	0.00053	0.00141	CbGeAlD
Carvedilol—ABCB1—female reproductive system—cervical cancer	0.000505	0.00134	CbGeAlD
Carvedilol—PTGS1—lymph node—cervical cancer	0.0005	0.00133	CbGeAlD
Carvedilol—ABCB1—female gonad—cervical cancer	0.00046	0.00122	CbGeAlD
Carvedilol—ABCB1—vagina—cervical cancer	0.000457	0.00121	CbGeAlD
Carvedilol—ABCB1—lymph node—cervical cancer	0.000295	0.000785	CbGeAlD
Carvedilol—ADRB3—Signaling Pathways—WNT2—cervical cancer	0.000145	0.000384	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—WNT2—cervical cancer	0.000145	0.000384	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—MTOR—cervical cancer	0.000145	0.000383	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—WNT2—cervical cancer	0.000145	0.000383	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD4—cervical cancer	0.000145	0.000382	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—NOTCH1—cervical cancer	0.000144	0.00038	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—WNT2—cervical cancer	0.000143	0.000378	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKAP13—cervical cancer	0.000141	0.000373	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKAP13—cervical cancer	0.000141	0.000372	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	0.000141	0.000372	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKAP13—cervical cancer	0.00014	0.00037	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKAP13—cervical cancer	0.000138	0.000365	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—STAT3—cervical cancer	0.000137	0.000363	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000136	0.000359	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—WNT2—cervical cancer	0.000135	0.000358	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—WNT2—cervical cancer	0.000133	0.000352	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—CASP3—cervical cancer	0.000133	0.000351	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKAP13—cervical cancer	0.000131	0.000346	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKAP13—cervical cancer	0.000129	0.00034	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TERT—cervical cancer	0.000129	0.00034	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CTNNB1—cervical cancer	0.000128	0.000339	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKAP13—cervical cancer	0.000128	0.000339	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKAP13—cervical cancer	0.000128	0.000338	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKAP13—cervical cancer	0.000127	0.000337	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKAP13—cervical cancer	0.000127	0.000336	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKAP13—cervical cancer	0.000126	0.000332	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000125	0.00033	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000125	0.00033	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—WNT5A—cervical cancer	0.000122	0.000321	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TAAR6—cervical cancer	0.000121	0.000321	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKAP13—cervical cancer	0.000119	0.000314	CbGpPWpGaD
Carvedilol—HIF1A—Disease—MTOR—cervical cancer	0.000118	0.000313	CbGpPWpGaD
Carvedilol—HIF1A—Disease—CD4—cervical cancer	0.000118	0.000313	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—WNT2—cervical cancer	0.000118	0.000313	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—FGFR3—cervical cancer	0.000118	0.000312	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKAP13—cervical cancer	0.000117	0.000309	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKAP13—cervical cancer	0.000114	0.000302	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—STAT3—cervical cancer	0.000112	0.000296	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—WNT5A—cervical cancer	0.000111	0.000293	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NOTCH1—cervical cancer	0.000111	0.000293	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TAAR6—cervical cancer	0.000111	0.000292	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—WNT5A—cervical cancer	0.00011	0.000291	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—WNT5A—cervical cancer	0.00011	0.000291	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	0.00011	0.00029	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—WNT5A—cervical cancer	0.00011	0.00029	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TAAR6—cervical cancer	0.00011	0.00029	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—WNT5A—cervical cancer	0.000108	0.000286	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TAAR6—cervical cancer	0.000108	0.000286	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	0.000106	0.000281	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—EGFR—cervical cancer	0.000106	0.00028	CbGpPWpGaD
Carvedilol—HIF1A—Disease—CTNNB1—cervical cancer	0.000105	0.000278	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—TP53—cervical cancer	0.000105	0.000277	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKAP13—cervical cancer	0.000104	0.000274	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—WNT5A—cervical cancer	0.000103	0.000271	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TAAR6—cervical cancer	0.000102	0.000271	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—EGFR—cervical cancer	0.000102	0.000269	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—WNT5A—cervical cancer	0.000101	0.000267	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TAAR6—cervical cancer	0.000101	0.000266	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	9.65e-05	0.000255	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	9.6e-05	0.000254	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—CTNNB1—cervical cancer	9.55e-05	0.000252	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—WNT2—cervical cancer	9.47e-05	0.00025	CbGpPWpGaD
Carvedilol—HIF1A—Disease—STAT3—cervical cancer	9.16e-05	0.000242	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CA9—cervical cancer	9.02e-05	0.000239	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CA9—cervical cancer	9.01e-05	0.000238	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—WNT5A—cervical cancer	8.96e-05	0.000237	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TAAR6—cervical cancer	8.95e-05	0.000237	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	8.65e-05	0.000229	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—WNT2—cervical cancer	8.63e-05	0.000228	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—WNT2—cervical cancer	8.55e-05	0.000226	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—WNT2—cervical cancer	8.45e-05	0.000223	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	8.33e-05	0.00022	CbGpPWpGaD
Carvedilol—HIF1A—Disease—EGFR—cervical cancer	8.32e-05	0.00022	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—STAT3—cervical cancer	8.32e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKAP13—cervical cancer	8.32e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	8.31e-05	0.00022	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—MTOR—cervical cancer	8.3e-05	0.000219	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—WNT2—cervical cancer	7.99e-05	0.000211	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	7.97e-05	0.000211	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—WNT2—cervical cancer	7.86e-05	0.000208	CbGpPWpGaD
Carvedilol—XDH—Metabolism—MTHFR—cervical cancer	7.81e-05	0.000206	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NOTCH2—cervical cancer	7.74e-05	0.000205	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NOTCH2—cervical cancer	7.72e-05	0.000204	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CASP3—cervical cancer	7.63e-05	0.000202	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKAP13—cervical cancer	7.58e-05	0.0002	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—EGFR—cervical cancer	7.56e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKAP13—cervical cancer	7.51e-05	0.000199	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKAP13—cervical cancer	7.41e-05	0.000196	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CTNNB1—cervical cancer	7.36e-05	0.000194	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CA9—cervical cancer	7.33e-05	0.000194	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—WNT5A—cervical cancer	7.18e-05	0.00019	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	7.08e-05	0.000187	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKAP13—cervical cancer	7.02e-05	0.000185	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—WNT2—cervical cancer	6.99e-05	0.000185	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKAP13—cervical cancer	6.9e-05	0.000183	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CA9—cervical cancer	6.73e-05	0.000178	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	6.55e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—WNT5A—cervical cancer	6.54e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—WNT2—cervical cancer	6.49e-05	0.000172	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—WNT5A—cervical cancer	6.48e-05	0.000171	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—STAT3—cervical cancer	6.41e-05	0.00017	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—WNT5A—cervical cancer	6.4e-05	0.000169	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CA9—cervical cancer	6.35e-05	0.000168	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HES1—cervical cancer	6.34e-05	0.000168	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HES1—cervical cancer	6.33e-05	0.000167	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	6.31e-05	0.000167	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—cervical cancer	6.23e-05	0.000165	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKAP13—cervical cancer	6.13e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—WNT5A—cervical cancer	6.06e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—WNT5A—cervical cancer	5.96e-05	0.000158	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EGFR—cervical cancer	5.83e-05	0.000154	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	5.7e-05	0.000151	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TERT—cervical cancer	5.56e-05	0.000147	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TERT—cervical cancer	5.55e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—WNT5A—cervical cancer	5.29e-05	0.00014	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—FGFR3—cervical cancer	5.1e-05	0.000135	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—FGFR3—cervical cancer	5.09e-05	0.000135	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CA9—cervical cancer	5.07e-05	0.000134	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOTCH2—cervical cancer	5.04e-05	0.000133	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	5e-05	0.000132	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	4.92e-05	0.00013	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—cervical cancer	4.89e-05	0.000129	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NOTCH1—cervical cancer	4.79e-05	0.000127	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NOTCH1—cervical cancer	4.78e-05	0.000126	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CA9—cervical cancer	4.78e-05	0.000126	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CA9—cervical cancer	4.74e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOTCH2—cervical cancer	4.59e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOTCH2—cervical cancer	4.55e-05	0.00012	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOTCH2—cervical cancer	4.49e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—cervical cancer	4.27e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOTCH2—cervical cancer	4.25e-05	0.000112	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	4.2e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOTCH2—cervical cancer	4.18e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HES1—cervical cancer	4.13e-05	0.000109	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CA9—cervical cancer	4.05e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HES1—cervical cancer	3.77e-05	9.95e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HES1—cervical cancer	3.73e-05	9.86e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOTCH2—cervical cancer	3.72e-05	9.82e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HES1—cervical cancer	3.68e-05	9.74e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—cervical cancer	3.67e-05	9.7e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—MTHFR—cervical cancer	3.66e-05	9.68e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—MTHFR—cervical cancer	3.66e-05	9.66e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TERT—cervical cancer	3.62e-05	9.57e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MTOR—cervical cancer	3.59e-05	9.49e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MTOR—cervical cancer	3.58e-05	9.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HES1—cervical cancer	3.48e-05	9.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	3.45e-05	9.13e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HES1—cervical cancer	3.43e-05	9.07e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—cervical cancer	3.43e-05	9.06e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—FGFR3—cervical cancer	3.32e-05	8.78e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CASP3—cervical cancer	3.3e-05	8.72e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TERT—cervical cancer	3.3e-05	8.72e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CASP3—cervical cancer	3.29e-05	8.71e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TERT—cervical cancer	3.27e-05	8.64e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TERT—cervical cancer	3.23e-05	8.53e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CTNNB1—cervical cancer	3.18e-05	8.41e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CTNNB1—cervical cancer	3.17e-05	8.39e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CA9—cervical cancer	3.12e-05	8.25e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOTCH1—cervical cancer	3.12e-05	8.25e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TERT—cervical cancer	3.05e-05	8.07e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HES1—cervical cancer	3.05e-05	8.05e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FGFR3—cervical cancer	3.03e-05	8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TERT—cervical cancer	3.01e-05	7.94e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FGFR3—cervical cancer	3e-05	7.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—MTHFR—cervical cancer	2.97e-05	7.86e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FGFR3—cervical cancer	2.96e-05	7.83e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOTCH1—cervical cancer	2.84e-05	7.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HES1—cervical cancer	2.83e-05	7.48e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOTCH1—cervical cancer	2.82e-05	7.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FGFR3—cervical cancer	2.8e-05	7.41e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—cervical cancer	2.79e-05	7.36e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOTCH1—cervical cancer	2.78e-05	7.35e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—cervical cancer	2.78e-05	7.35e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—STAT3—cervical cancer	2.77e-05	7.33e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—STAT3—cervical cancer	2.77e-05	7.31e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FGFR3—cervical cancer	2.76e-05	7.29e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—MTHFR—cervical cancer	2.73e-05	7.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TERT—cervical cancer	2.67e-05	7.06e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOTCH1—cervical cancer	2.63e-05	6.95e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOTCH1—cervical cancer	2.59e-05	6.84e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—MTHFR—cervical cancer	2.58e-05	6.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—cervical cancer	2.53e-05	6.69e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—cervical cancer	2.52e-05	6.66e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—cervical cancer	2.52e-05	6.65e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—cervical cancer	2.51e-05	6.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TERT—cervical cancer	2.48e-05	6.56e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—cervical cancer	2.48e-05	6.55e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FGFR3—cervical cancer	2.45e-05	6.48e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—cervical cancer	2.34e-05	6.2e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MTOR—cervical cancer	2.34e-05	6.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—cervical cancer	2.31e-05	6.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOTCH1—cervical cancer	2.3e-05	6.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	2.28e-05	6.02e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CASP3—cervical cancer	2.15e-05	5.68e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	2.14e-05	5.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MTOR—cervical cancer	2.13e-05	5.63e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—cervical cancer	2.12e-05	5.59e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—cervical cancer	2.11e-05	5.58e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MTOR—cervical cancer	2.11e-05	5.58e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MTOR—cervical cancer	2.08e-05	5.51e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CTNNB1—cervical cancer	2.07e-05	5.48e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MTHFR—cervical cancer	2.06e-05	5.44e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—cervical cancer	2.05e-05	5.42e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MTOR—cervical cancer	1.97e-05	5.21e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CASP3—cervical cancer	1.96e-05	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CASP3—cervical cancer	1.94e-05	5.13e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MTOR—cervical cancer	1.94e-05	5.13e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MTHFR—cervical cancer	1.94e-05	5.12e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MTHFR—cervical cancer	1.92e-05	5.08e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CASP3—cervical cancer	1.92e-05	5.07e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	1.9e-05	5.03e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—cervical cancer	1.89e-05	4.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—cervical cancer	1.87e-05	4.95e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—cervical cancer	1.85e-05	4.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CASP3—cervical cancer	1.81e-05	4.79e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—cervical cancer	1.81e-05	4.78e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—cervical cancer	1.78e-05	4.72e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—cervical cancer	1.75e-05	4.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MTOR—cervical cancer	1.72e-05	4.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—cervical cancer	1.72e-05	4.55e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—cervical cancer	1.65e-05	4.35e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—cervical cancer	1.64e-05	4.34e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—cervical cancer	1.64e-05	4.34e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—cervical cancer	1.63e-05	4.31e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—cervical cancer	1.61e-05	4.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MTOR—cervical cancer	1.6e-05	4.23e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—cervical cancer	1.59e-05	4.19e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—cervical cancer	1.53e-05	4.04e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—cervical cancer	1.52e-05	4.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—cervical cancer	1.5e-05	3.96e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—cervical cancer	1.5e-05	3.95e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—cervical cancer	1.48e-05	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—cervical cancer	1.47e-05	3.89e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—cervical cancer	1.46e-05	3.87e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	1.42e-05	3.75e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—cervical cancer	1.38e-05	3.66e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—cervical cancer	1.38e-05	3.64e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—cervical cancer	1.36e-05	3.6e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—cervical cancer	1.33e-05	3.52e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—cervical cancer	1.27e-05	3.35e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—cervical cancer	1.26e-05	3.32e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—cervical cancer	1.24e-05	3.29e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—cervical cancer	1.24e-05	3.27e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—cervical cancer	1.23e-05	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—cervical cancer	1.21e-05	3.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—cervical cancer	1.16e-05	3.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—cervical cancer	1.14e-05	3.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—cervical cancer	1.12e-05	2.97e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—cervical cancer	1.02e-05	2.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—cervical cancer	9.44e-06	2.5e-05	CbGpPWpGaD
